Gene

TP53

tumor protein p53

Explore in graph →CI-GENE-00035913HGNC:11998 ENSG00000141510 NCBI 7157 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (408)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 151–200 of 408 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TP53 M246R1
(functional)	—UNRESOLVED	Functional	D	Supports Dominant Negative	3	submitted

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022) msk_spectrum_tme_2022	unmapped	Ssm	81	82

Literature

Linked publications (58)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 58 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
· Blood · 2016 · PMID 26837699 · validated civic_curation pubmed
TP53 mutation and survival in chronic lymphocytic leukemia.
· J Clin Oncol · 2010 · PMID 20697090 · validated civic_curation pubmed
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
· Leukemia · 2015 · PMID 24943832 · validated civic_curation pubmed
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
· J Clin Oncol · 2017 · PMID 28453411 · validated

TP53 M246T1
(functional)	—UNRESOLVED	Functional	D	Supports Loss Of Function	2	submitted	EID9458 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic

TP53 M246T1

(functional)

—UNRESOLVED

Functional

Supports Loss Of Function

submitted

EID9458

Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC)

PMID 20407015 · Jordan et al., 2010 · Open in CIViC

TP53 Mutation47
(prognostic)	Chronic Lymphocytic Leukemia	Prognostic	A	Supports Poor Outcome	5	accepted	EID1507 In a cohort of 406 patients with CLL, those patients with clonal or sub-clonal mutations in TP53 had significantly shorter overall survival (HR: 1.71; 95% CI: 1.28-2.26; P = .0001). PMID 26837699 · Nadeu et al., 2016 · Open in CIViC	civic
〃	Chronic Lymphocytic Leukemia	Prognostic	B	Supports Poor Outcome	5	accepted	EID1452 The authors analyzed 328 patients with CLL, of which 28 were identified to have TP53 mutations. Patients with TP53 mutations were found to have significantly shorter progression-free (HR = 3.8; P < 0.… (full text at CIViC) PMID 20697090 · Zenz et al., 2010 · Open in CIViC	civic
〃	Chronic Lymphocytic Leukemia	Prognostic	B	Supports Poor Outcome	5	accepted	EID1485 In a multivariate analysis of 774 CLL patients, TP53 aberrations were significantly correlated with shorter time to first treatment (HR=2.081; 95% CI=1.431-3.021). This finding was independent of IGHV… (full text at CIViC) PMID 24943832 · Baliakas et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Prognostic	B	Supports N/A	5	accepted	EID2999 A pooled analysis to investigate the prognostic and predictive roles of TP53/KRAS and TP53/EGFR comutations (cm) in randomized trials of adjuvant chemotherapy compared to observational therapy encompa… (full text at CIViC) PMID 28453411 · Shepherd et al., 2017 · Open in CIViC	civic
(predisposing)	Medulloblastoma, SHH-Activated, TP53-MutantALIAS	Predisposing	B	Supports Predisposition	5	submitted	EID8346 This international, multicenter study analyzed patients with medulloblastoma (MB) from both retrospective and prospective cohorts in order to identify consensus MB predisposition genes. A total of 102… (full text at CIViC) PMID 29753700 · Waszak et al., 2018 · Open in CIViC	civic
(prognostic)	Medulloblastoma, SHH-Activated	Prognostic	B	Supports Poor Outcome	5	accepted	EID8347 In the childhood (≥4.3 years) SHH-MB subgroup, TP53 mutations (n=13) are associated with shorter progression-free survival (PFS) compared to the no mutation group (n=35) (HR, 3.47; 95% CI, 1.29 to 9.3… (full text at CIViC) PMID 28545823 · Schwalbe et al., 2017 · Open in CIViC	civic
〃	Esophageal Squamous Cell CarcinomaALIAS	Prognostic	B	Supports Poor Outcome	4	accepted	EID519 In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival. PMID 19941080 · Yamasaki et al., 2010 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID520 In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, in multivariate analysis those with mutations in TP53 had worse event-free survival than patients without mutations… (full text at CIViC) PMID 22699455 · Krentz et al., 2013 · Open in CIViC	civic
〃	Myelodysplastic SyndromeCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID521 In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild-type patients. PMID 24836762 · Bally et al., 2014 · Open in CIViC	civic
〃	Myeloid Neoplasm	Prognostic	B	Supports Poor Outcome	4	accepted	EID522 In patients with myeloma, those with mutations in TP53 had worse overall survival than those without. PMID 17215851 · Chng et al., 2007 · Open in CIViC	civic
〃	Head and Neck Squamous Cell Carcinoma	Prognostic	B	Does Not Support Poor Outcome	4	accepted	EID523 Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with … (full text at CIViC) PMID 11325447 · Alsner et al., 2001 · Open in CIViC	civic
〃	Head and Neck Squamous Cell Carcinoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID524 Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations. Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of l… (full text at CIViC) PMID 11325447 · Alsner et al., 2001 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID640 In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall … (full text at CIViC) PMID 21747090 · Hof et al., 2011 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID1018 In a study of 97 patients with AML treated with HSCT, 40 had TP53 mutations comprising a total of 44 mutations. Patients with a TP53 mutation had a reduced three year probability of overall survival … (full text at CIViC) PMID 26771088 · Middeke et al., 2016 · Open in CIViC	civic
〃	Chronic Lymphocytic Leukemia	Prognostic	B	Supports Poor Outcome	4	accepted	EID1451 In a study of 126 patients with long-term follow-up, TP53 mutations were significantly associated with shorter median survival in patients (P = 0.002) from time of diagnosis. The median survival from … (full text at CIViC) PMID 18689542 · Zenz et al., 2008 · Open in CIViC	civic
〃	Myelodysplastic SyndromeCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	submitted	EID6943 In a study of 439 patients with myelodysplastic syndrome, patients with TP53 mutations (N=33) has worse overall survival than wildtype patients (N=406) (P<0.001 univariate). This difference was also o… (full text at CIViC) PMID 21714648 · Bejar et al., 2011 · Open in CIViC	civic
〃	MedulloblastomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	submitted	EID7963 This study showed that patients with TP53 mutated medulloblastoma (8/49, 16%) exhibited worse prognosis compared to those with wildtype medulloblastoma (41/49, 84%). A 5-year overall survival of 0% wa… (full text at CIViC) PMID 20142599 · Tabori et al., 2010 · Open in CIViC	civic
〃	MedulloblastomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	submitted	EID7964 This study examined the prognostic implication of TP53 mutation status in different molecular subgroups of medulloblastoma. A discovery cohort of 397 patients and a validation cohort of 156 cases were… (full text at CIViC) PMID 23835706 · Zhukova et al., 2013 · Open in CIViC	civic
(diagnostic)	Medulloblastoma, SHH-Activated, TP53-MutantALIAS	Diagnostic	B	Supports Positive	4	submitted	EID8345 One of the goals of this study is to understand the biology of the sonic-hedgehog subgroup of medulloblastoma (SHH-MB) across different age groups. A large cohort of patients (n=133) with SHH-MB, incl… (full text at CIViC) PMID 24651015 · Kool et al., 2014 · Open in CIViC	civic
(prognostic)	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	3	accepted	EID393 In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53. Multivariate Cox … (full text at CIViC) PMID 9569050 · Berns et al., 1998 · Open in CIViC	civic
〃	Head and Neck Squamous Cell Carcinoma	Prognostic	B	Does Not Support Poor Outcome	3	accepted	EID518 Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutati… (full text at CIViC) PMID 8901856 · Koch et al., 1996 · Open in CIViC	civic
〃	Chronic Lymphocytic Leukemia	Prognostic	B	Supports Poor Outcome	3	accepted	EID1450 A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated pat… (full text at CIViC) PMID 8241511 · el Rouby et al., 1993 · Open in CIViC	civic
〃	Chronic Lymphocytic Leukemia	Prognostic	B	Supports Poor Outcome	3	accepted	EID1478 In the CLL4 trial assessing first line treatment with chlorambucil or fludarabine with or without cyclophosphamide, patients with TP53 mutations experienced poorer overall response rates (27% vs 83%),… (full text at CIViC) PMID 21483000 · Gonzalez et al., 2011 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Prognostic	B	Supports Poor Outcome	3	submitted	EID6031 In an analysis of 321 patients with lung adenocarcinoma who received potentially curative pulmonary resection, patients with TP53 mutated tumors (N=115, exons 4-10 evaluated) had significantly poorer … (full text at CIViC) PMID 19096302 · Kosaka et al., 2009 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Prognostic	B	Supports Poor Outcome	3	submitted	EID6032 Analysis of 135 patients with chemotherapy naive lung adenocarcinoma, TP53 mutations were associated with reduced progression free survival (p = 0.0014, log rank test) using primary resection specimen… (full text at CIViC) PMID 22980975 · Imielinski et al., 2012 · Open in CIViC	civic
〃	GlioblastomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	submitted	EID7976 In a trial of 68 glioblastoma patients treated with either temozolomide or semustine, 24 patients were found to have TP53 mutations at codons 175, 248, or 273. Patients with TP53 mutation were found t… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC	civic
〃	Adrenal Cortical CarcinomaALIAS	Prognostic	B	Supports Poor Outcome	2	accepted	EID1028 TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098). Of 20 patients studied, 5 had coding mutation in TP53. Four of t… (full text at CIViC) PMID 15922892 · Sidhu et al., 2005 · Open in CIViC	civic
(oncogenic)	Burkitt Lymphoma	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11825 Described in many studies PMID 30617194 · Grande et al., 2019 · Open in CIViC	civic
(prognostic)	Mantle Cell Lymphoma	Prognostic	E	Supports Poor Outcome	4	submitted	EID11894 This study confirmed clinical associations between TP53 and NOTCH1 with poor outcome. PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC	civic
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11913 This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC) PMID 21796119 · Morin et al., 2011 · Open in CIViC	civic
〃	Mantle Cell Lymphoma	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11893 Through a meta-analysis of exome and whole genome sequencing data, this study identified 18 genes that were significantly enriched for mutations in MCL (including TP53). PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC	civic
Alemtuzumab	Chronic Lymphocytic Leukemia	Predictive	B	Supports Sensitivity Response	2	accepted	EID1481 Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statis… (full text at CIViC) PMID 14726385 · Lozanski et al., 2004 · Open in CIViC	civic
Chemotherapy	Gastric Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID850 In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.7… (full text at CIViC) PMID 24740294 · Xu et al., 2014 · Open in CIViC	civic
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1145 A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-beari… (full text at CIViC) PMID 22425996 · Chen et al., 2012 · Open in CIViC	civic
Doxorubicin	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	4	accepted	EID851 In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-ind… (full text at CIViC) PMID 22698404 · Jackson et al., 2012 · Open in CIViC	civic
Cisplatin + Doxorubicin + EtoposideCombination	Gastric CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	1	accepted	EID2820 In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
Doxorubicin + EprenetapoptCombination	Malignant Ovarian Neoplasm	Predictive	D	Supports Sensitivity Response	4	submitted	EID12011 This study examined the combined effects of APR-246 and doxorubicin in doxorubicin-resistant ovarian cancer cell lines. It revealed a decrease in IC50 value for doxorubicin from 0.95±0.11 μM to 0.12±0… (full text at CIViC) PMID 26086967 · Mohell et al., 2015 · Open in CIViC	civic
Azacitidine + EprenetapoptCombination	Myelodysplastic SyndromeCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID12029 In this phase 1/2 clinical trial, 55 patients (40 MDS, 11 AML, 4 MDS/myeloproliferative neoplasms) with myelodysplastic syndromes harbouring TP53 mutations were treated with a combination of eprenetap… (full text at CIViC) PMID 33449813 · Sallman et al., 2021 · Open in CIViC	civic
Cisplatin + EprenetapoptCombination	Malignant Ovarian Neoplasm	Predictive	D	Supports Sensitivity Response	4	submitted	EID12010 The combination effect of APR-246 and cisplatin was studied in cisplatin-resistant ovarian cancer cell lines. A decrease in IC50 value from 52±11 to 3.2±0.8 μM (p <0.05) for cisplatin was recorded in… (full text at CIViC) PMID 26086967 · Mohell et al., 2015 · Open in CIViC	civic
Eprenetapopt + PembrolizumabCombination	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	3	submitted	EID12033 In this phase 1b study, the combination treatment of eprenetapopt (APR-246) and pembrolizumab was investigated for its efficacy in patients with advanced or metastatic solid tumors. Out of the 37 pati… (full text at CIViC) PMID 36084396 · Park et al., 2022 · Open in CIViC	civic
Gemcitabine	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	2	submitted	EID8282 In this retrospective analysis, tumor samples from 101 patients from the CONKO-001 trial, who received curatively intended surgery for pancreatic adenocarcinoma (PDAC) followed by adjuvant chemotherap… (full text at CIViC) PMID 32234756 · Sinn et al., 2020 · Open in CIViC	civic
Tamoxifen	Malignant Breast Neoplasm	Predictive	C	Supports Resistance	1	accepted	EID2784 In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31… (full text at CIViC) PMID 10786679 · Berns et al., 2000 · Open in CIViC	civic
Temozolomide	GlioblastomaCURATED_BROADER	Predictive	B	Supports Resistance	3	submitted	EID7978 In a trial of 68 glioblastoma patients treated with either temozolomide or semustine, 24 patients were found to have TP53 mutations at codons 175, 248, or 273. Kaplan-Meier analysis of the 35 patients… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC	civic
VEGF/VEGFR Inhibitors	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID11709 In this trial involving 500 patients, 188 individuals received treatment with VEGF/VEGFR inhibitors. Among them, 106 patients had tumors containing TP53 mutations. The analysis revealed a higher rate … (full text at CIViC) PMID 27466356 · Wheler et al., 2016 · Open in CIViC	civic
Venetoclax	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Predictive	B	Does Not Support Resistance	2	submitted	EID6074 In patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, patients with deletion 17p and/or mutations in TP53 (N=24) were not more likely to have progressive dis… (full text at CIViC) PMID 28473407 · Anderson et al., 2017 · Open in CIViC	civic
〃	Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaALIAS	Predictive	B	Does Not Support Resistance	2	rejected	EID12076 In patients with relapsed /refractory chronic lymphocytes leukemia or small lymphocytic lymphoma, patients with deletion 17p and/or mutations in TP53 (N=24) were not more likely to have progressive di… (full text at CIViC) PMID 28473407 · Anderson et al., 2017 · Open in CIViC	civic
Vismodegib	Medulloblastoma, SHH-Activated, TP53-MutantALIAS	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID8348 Two phase II studies (PBTC-025B, n=31, age ≥ 22 years; PBTC-032, n=12, age 3-21 years) assessed the targeted efficacy of vismodegib, an SMO inhibitor, in patients with recurrent sonic hedgehog subgrou… (full text at CIViC) PMID 26169613 · Robinson et al., 2015 · Open in CIViC	civic